Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...
PSA launched comic book and magazine grading in July and will now directly compete against industry leader CGC as well as ...
Patients with D2T-PsA can be stratified into inflammatory and noninflammatory phenotypes, with the former linked to higher sonographic activity.
September is Prostate Cancer Awareness Month, and when many men choose to get check-ups. Though the month is nearly over, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback